

P L F Giangrande

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/195134/publications.pdf>

Version: 2024-02-01

31
papers

2,225
citations

471509

17
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

2101
citing authors

#	ARTICLE	IF	CITATIONS
1	Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. <i>Nature Medicine</i> , 1997, 3, 212-217.	30.7	1,096
2	Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. <i>Nature</i> , 1994, 369, 403-407.	27.8	438
3	Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. <i>Thrombosis and Haemostasis</i> , 2017, 117, 252-261.	3.4	96
4	Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven [®]] in elective orthopaedic surgery in haemophilic patients with inhibitors. <i>Haemophilia</i> , 2009, 15, 501-508.	2.1	77
5	Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia. <i>Haemophilia</i> , 2017, 23, 511-520.	2.1	63
6	Creuth III: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. <i>Haemophilia</i> , 2014, 20, 322-325.	2.1	43
7	Haemophilia B: Christmas disease. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1517-1524.	1.8	38
8	Safety and efficacy of KOGENATER Bayer in previously untreated patients (PUPs) and minimally treated patients (MTPs). <i>Haemophilia</i> , 2002, 8, 19-22.	2.1	35
9	European principles of inhibitor management in patients with haemophilia. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 66.	2.7	33
10	Porcine factor VIII. <i>Haemophilia</i> , 2012, 18, 305-309.	2.1	31
11	Low factor consumption for major surgery in haemophilia B with long-acting recombinant glycoPEGylated factor IX. <i>Haemophilia</i> , 2017, 23, 67-76.	2.1	31
12	A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate. <i>British Journal of Haematology</i> , 1994, 87, 782-788.	2.5	27
13	Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs. <i>International Journal of Laboratory Hematology</i> , 1999, 21, 125-128.	0.2	22
14	Treatment of hemophilia: recombinant factors only? Yes. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 214-215.	3.8	22
15	Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors. <i>Blood Reviews</i> , 2015, 29, S9-S18.	5.7	21
16	Long-term safety and efficacy of N8-CP in previously treated adults and adolescents with hemophilia A: Final results from pathfinder2. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 5-14.	3.8	18
17	Fondaparinux (Arixtra): a new anticoagulant. <i>International Journal of Clinical Practice</i> , 2002, 56, 615-7.	1.7	18
18	Adverse events in the prophylaxis of haemophilia. <i>Haemophilia</i> , 2003, 9, 50-56.	2.1	15

#	ARTICLE	IF	CITATIONS
19	Gene therapy for hemophilia? No. Journal of Thrombosis and Haemostasis, 2004, 2, 1236-1237.	3.8	15
20	Kreuth ^{IV}: European consensus proposals for treatment of haemophilia with coagulation factor concentrates. Haemophilia, 2017, 23, 370-375.	2.1	15
21	Fibrin Sealant Reduces Blood Loss in Total Hip Arthroplasty. HIP International, 1999, 9, 127-132.	1.7	14
22	Viral pharmacovigilance study of haemophiliacs receiving porcine factor VIII. Haemophilia, 2002, 8, 798-801.	2.1	12
23	The European standards of Haemophilia Centres. Blood Transfusion, 2014, 12 Suppl 3, s525-30.	0.4	12
24	Management of difficult-to-treat inhibitor patients. Haemophilia, 2010, 16, 52-57.	2.1	9
25	Delayed splenic rupture in a haemophiliac. International Journal of Laboratory Hematology, 1999, 21, 215-218.	0.2	6
26	European principles of inhibitor management in patients with haemophilia: implications of new treatment options. Orphanet Journal of Rare Diseases, 2020, 15, 219.	2.7	6
27	Treatment of haemophilia in the United Kingdom 1981-1996. Haemophilia, 2001, 7, 349-359.	2.1	5
28	Present and future challenges in the treatment of haemophilia: the patient's perspective. Blood Transfusion, 2013, 11 Suppl 4, s82-5.	0.4	4
29	Treatment of patients with haemophilia and inhibitory antibodies. Indian Journal of Pediatrics, 2003, 70, 655-659.	0.8	3
30	Pregnancy in women with inherited bleeding disorders. , 2005, , 16-26.		0
31	Hepatitis C and bleeding disorders in Europe. The Journal of Haemophilia Practice, 2018, 5, 50-65.	0.4	0